CyclontaneЦиклонтан
A synthetic adamantane derivative, also called ADK-638, studied on its own and in a formulation with sodium oxybate.
What the studies found
Animal research · 2022
Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability
Study of multiple preparations
Cyclantane, Ladasten and memantine partially restored attention in the low-attention subgroup, but worsened attention in the initially high-attention subgroup by 40–47% relative to controls. Exploratory and locomotor measures did not change in parallel.
Study notes · methods, sources and limitations
Participants or model CD-1 mice separated by baseline attention phenotype; three administrations
Important limitations
- Phenotype-dependent mouse behavior is not evidence for human ADHD treatment or general cognitive enhancement. Dose, route and repeated-testing effects limit extrapolation; the names Cyclantane and Cyclontane refer here to ADK-638.
Pharmacokinetics and Pharmacodynamics. 2022;(1):3–8 · Publication record
Experiment described in a patent · 2018
Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis
- Wheel activity
- Approximately 700 revolutions with the combination versus 200 with saline; baseline about 900Desynchronized ratsThird day
- REM-sleep duration
- Reported 1.7-fold longer than untreated desynchronization; 62.5% versus 30% exceeded the stated REM thresholdThreshold: REM duration >50% of the baseline group average
- Persisting abnormality
- REM-onset latency remained approximately twice baseline; wakefulness remained elevatedImprovement versus injury did not mean normalization
The combination was investigated for activity rhythms, performance, operant learning and EEG sleep. REM duration exceeded the untreated desynchronosis group, but REM latency remained prolonged relative to baseline: recovery was incomplete.
More reported outcomes
- Acute observations
- No deaths or listed overt neurological/behavioral abnormalities reportedAnimal observations only14 days
Study notes · methods, sources and limitations
Participants or model Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.
Design Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.
Important limitations
- Combination findings cannot establish Cyclontane’s independent effect; patent evidence does not establish human efficacy or safety. No clinical sleep benefit or safe self-use regimen follows from these experiments.
- The combination does not isolate Cyclontane, and sleep comparisons vary by experiment. Animal safety observations do not establish human safety of this combination.
RU2674342C2; filed 28 November 2016; Russian Federation represented by Ministry of Defense · Patent report
About Cyclontane
Names in this research collection
ADK-638 · Cyclantane · Циклантан
Research background
1-Hydroxy-4-cyclohexylaminoadamantane hydrochloride (ADK-638), an experimental hydroxyadamantane. Individual-compound experiments and the sodium-oxybate formulation are separate evidence.
- Compound class
- Experimental adamantane / analogue
- Research collection
- Actoprotection & occupational pharmacology · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Human efficacy results unavailable
Study methods
Source-specific animal, chemistry, patent or dissertation evidence
Independent replication
Independent replication not established; translations are not separate experiments
Source access
Access and review depth appear with each linked record
Safety evidence
Human safety and interactions not established; animal activity is not a safe-use recommendation
Open a topic for the evidence assessment.
Patents and claimed inventions
These 2 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Experiment described in a patent · 2018
Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis
The combination was investigated for activity rhythms, performance, operant learning and EEG sleep. REM duration exceeded the untreated desynchronosis group, but REM latency remained prolonged relative to baseline: recovery was incomplete.
Wheel activity · Approximately 700 revolutions with the combination versus 200 with saline; baseline about 900 · Desynchronized rats · Third day
Study notes and original source
Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis
Format: Patent · Reviewed: Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
· RU2674342C2; filed 28 November 2016; Russian Federation represented by Ministry of Defense
The combination was investigated for activity rhythms, performance, operant learning and EEG sleep. REM duration exceeded the untreated desynchronosis group, but REM latency remained prolonged relative to baseline: recovery was incomplete.
Results and tables
Reported patent results
Reported findings
Some activity and REM-sleep measures improved relative to untreated desynchronization, while sleep timing remained abnormal.
Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.
Population or model Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Wheel activity | Approximately 700 revolutions with the combination versus 200 with saline; baseline about 900 | Desynchronized rats · Third day |
| REM-sleep duration | Reported 1.7-fold longer than untreated desynchronization; 62.5% versus 30% exceeded the stated REM threshold | Threshold: REM duration >50% of the baseline group average |
| Persisting abnormality | REM-onset latency remained approximately twice baseline; wakefulness remained elevated | Improvement versus injury did not mean normalization |
| Acute observations | No deaths or listed overt neurological/behavioral abnormalities reported | Animal observations only · 14 days |
The combination does not isolate Cyclontane, and sleep comparisons vary by experiment. Animal safety observations do not establish human safety of this combination.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- Combination findings cannot establish Cyclontane’s independent effect; patent evidence does not establish human efficacy or safety.
- No clinical sleep benefit or safe self-use regimen follows from these experiments.
Reviewed 2026-11-06.
Animal research · 2022
Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability
Cyclantane, Ladasten and memantine partially restored attention in the low-attention subgroup, but worsened attention in the initially high-attention subgroup by 40–47% relative to controls. Exploratory and locomotor measures did not change in parallel.
Study notes and original source
Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability
Format: Journal article; full-text reproduction · Reviewed: Abstract, identity passage and selected methods reviewed
N. A. Sukhorukova, R. M. Salimov, G. I. Kovalev · Pharmacokinetics and Pharmacodynamics. 2022;(1):3–8
Cyclantane, Ladasten and memantine partially restored attention in the low-attention subgroup, but worsened attention in the initially high-attention subgroup by 40–47% relative to controls. Exploratory and locomotor measures did not change in parallel.
- Population / setting
- CD-1 mice separated by baseline attention phenotype; three administrations
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- Phenotype-dependent mouse behavior is not evidence for human ADHD treatment or general cognitive enhancement.
- Dose, route and repeated-testing effects limit extrapolation; the names Cyclantane and Cyclontane refer here to ADK-638.
Reviewed 2026-10-03.
Experiment described in a patent · 2003
Original Cyclontane / ADK-638 patent trail
The later patent cites this earlier Cyclontane development record. Original behavioral and toxicity comparisons require direct verification before numerical claims are reproduced.
Study notes and original source
Original Cyclontane / ADK-638 patent trail
· RU2196575C2; cited in later RU2674342C2
The later patent cites this earlier Cyclontane development record. Original behavioral and toxicity comparisons require direct verification before numerical claims are reproduced.
Results and tables
Reported patent results
Findings described in words
The patent reports increased running-to-exhaustion performance and stimulant-related behavioral effects.
Original Cyclontane/ADK-638 animal pharmacology, including treadmill groups of 8 preselected rats.
Population or model Original Cyclontane/ADK-638 animal pharmacology, including treadmill groups of 8 preselected rats.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Treadmill performance | Significantly longer running-to-exhaustion at selected tested exposures | 8 rats per group; exact table means not transcribed |
| Behavioral pharmacology | Anti-cataleptic activity and stimulant-like responses described | Model-specific comparisons do not establish human superiority to Bromantane |
Preselected animal performance is not a human occupational outcome, and the patent’s clinical recommendations exceed the experiments. Findings belong to ADK-638 rather than every related cage compound.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Original Cyclontane/ADK-638 animal pharmacology, including treadmill groups of 8 preselected rats.
- Source reviewed
- Prior-art citation followed from the 2018 patent; original retrieval unsuccessful.
Study limitations
- Bibliographic lead only; neither potency ratios nor toxicity estimates from secondary accounts are treated as verified here.
Reviewed 2026-11-06.
Explore related historical combinations ↗
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗